Research Paper Volume 11, Issue 2 pp 549—572

S100A13 promotes senescence-associated secretory phenotype and cellular senescence via modulation of non-classical secretion of IL-1α

class="figure-viewer-img"

Figure 6. S100A13 modulates multiple SASP and cellular senescence regulators. (AD) HCT116 cells were transfected with the control, S100A13 wild type or mutant type (A and C), or transfected with the control (siNC) or two independent siRNAs against S100A13 (B and D), and then treated with Dox (100 nM) for 3 or 4 days. Then cell lysates were subjected to western blot analysis for the indicated proteins. (E) HCT116 cells were transfected with wild type S100A13, and treated with Dox (100 nM) for 3 days. Control IgG (0.6 ug/ml) or neutralizing antibody IL-1a (0.6 ug/ml) were added for the last 2 days. Then the indicated proteins were analyzed by Western blot. (F) HCT116 cells were transfected with siRNA#2 against S100A13, and treated with Dox (100 nM) for 3 days. Solvent or recombinant IL-1a protein (300 ng/ml) were added for the last 2 days. Then the indicated proteins were analyzed by Western blot. (G and H) ER:Ras IMR90 cells were given 4-OHT for toal 6 days in the presence of the indicated doses of Amlexanox (G); or TTM (H); then the indicated proteins were analyzed by Western blot. Three independent experiments were performed.